Acarix

Summary of instructions and important dates
Holders of warrants who wish to exercise these to subscribe for shares shall give notice regarding such exercise well before May 16, 2023. Warrants that have not been exercised or sold before then expire without value. Holders who do not wish to exercise their warrants can sell them. Trading in the warrants continues until May 12, 2023.

Detailed information and instructions for subscription
Exercise of nominee-registered warrants
Holders who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of warrants by contacting their nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before 16 May 2023 as different nominees have different processing times.

Exercise of directly registered warrants
Holders who have their holding of warrants directly registered (holding in VP account) must notify the exercise of warrants by submitting an application form for the exercise, so that the application form is received by the issuing agent Hagberg & Aneborn Fondkommission no later than May 16, 2023.

The application form is available on the Company's, the issuing agent's and Redeye AB's respective websites (www.acarix.com, www.hagberganeborn.se, www.redeye.se). Please note that payment for the new shares must be received by Hagberg & Aneborn Fondkommission no later than May 16, 2023 in accordance with the instructions on the application form.

Trading in warrants
Holders who do not wish to exercise their warrants may sell them on the Nasdaq First North Growth Market. The warrants are traded until and including 12 May 2023 under the short name ACARIX TO 2022U and with ISIN SE0019176256. Warrants that are not exercised by May 16, 2023 or sold by May 12, 2023 at the latest expire without value.

Outcome and delivery of new shares
The outcome of the exercise of the warrants will be published via press release around May 19, 2023. Shares that have been subscribed and paid for may be registered in the subscriber's securities depository as interim shares (IA) until registration of the issue is completed with the Swedish Companies Registration Office, whereupon interim shares are automatically changed to ordinary shares in Acarix.

Number of warrants and possible issue proceeds
The number of warrants amounts to 116,958,915. Upon full exercise of all warrants, Acarix will receive approximately 21.6 MSEK before issue costs. Upon full exercise of all warrants, the number of shares in Acarix will increase by 58,479,457 shares to a total of 431,810,566 shares, and the share capital will increase by approximately SEK 584,794.57 to approximately SEK 4,318,105.66. This entails a dilution of approximately 13 percent, taking into account shares issued on April 4, 2023, based on the number of shares in Acarix after full exercise of all warrants.

Complete terms and conditions for the warrants
Complete terms and conditions for the warrants are available on the Company's website and in the prospectus prepared by the board of Acarix in connection with the rights issue in 2022. The prospectus is available on the Company's, the issuing agent's and Redeye's respective websites. It is also available on the Swedish Financial Supervisory Authority's website www.fi.se.

Invesor presentations
Acarix will present at Redeye Investor Forum Online on May 4, Redeye Medtech event on May 10 and Redeye Live Q on May 11. Information about the events is available on Redeye's website. Additional investor presentations may be organized during the exercise period. The invitation to these will be presented on the respective websites of Acarix and Redeye.

Advisers
Redeye AB is acting as financial adviser and Hagberg & Aneborn Fondkommission AB is acting as issuing agent in connection with the transaction.